[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100564212":3},{"organization":4,"outcomesModule":7,"designInfo":42,"detailedDescription":45,"studyPopulation":46,"armGroups":47,"interventions":41,"overallOfficials":41,"centralContacts":57,"locations":64,"responsibleParty":150,"collaborators":154,"id":161,"slug":41,"hasResults":162,"nctId":163,"briefTitle":164,"officialTitle":165,"acronym":166,"eligibilityCriteria":167,"healthyVolunteers":162,"sex":168,"minAge":169,"maxAge":41,"enrollmentInfo":170,"targetDuration":41,"studyType":173,"phases":41,"briefSummary":174,"conditions":175,"keywords":177,"overallStatus":67,"whyStopped":41,"lastUpdateSubmitDate":181,"lastUpdatePostDateStruct":182,"startDateStruct":185,"completionDateStruct":187,"leadSponsor":189,"locationsCount":190},{"fullName":5,"class":6},"Scientific Institute San Raffaele","OTHER",{"primaryOutcomes":8,"secondaryOutcomes":20,"otherOutcomes":41},[9,13,17],{"measure":10,"description":11,"timeFrame":12},"The perioperative complication of video-assisted thoracoscopic surgery (VATS) approach","The investigators will measure the perioperative complications of VATS approach in patients who received neoadjuvant chemo-immunotherapy. Complications will be categorized according to the Clavien-Dindo scale.","30-90 days after surgery",{"measure":14,"description":15,"timeFrame":16},"The perioperative complications of robotic approach","The investigators will measure the perioperative complications of robotic lung resection in patients who received neoadjuvant chemo-immunotherapy. Complications will be categorized according to the Clavien-Dindo scale.","from the surgery at 30-90 days after",{"measure":18,"description":19,"timeFrame":12},"The perioperative complications of the open approach","The investigators will measure the perioperative complications of open approach in patients who received neoadjuvant chemo-immunotherapy. Complications will be categorized according to the Clavien-Dindo scale.",[21,25,28,31,34,37],{"measure":22,"description":23,"timeFrame":24},"Duration of surgery","Duration of the surgery based on the approach measured in minutes","from 30 days after surgery",{"measure":26,"description":27,"timeFrame":24},"Quality of lymphadenectomy","Number of lymphonodes station resected",{"measure":29,"description":30,"timeFrame":24},"Conversion rate","Number of surgery procedures converted",{"measure":32,"description":33,"timeFrame":24},"Radicality of the resection","Radicality of the resection in the approaches",{"measure":35,"description":36,"timeFrame":24},"Oncological treatment","Response of the patient to oncological treatment",{"measure":38,"description":39,"timeFrame":40},"Survival analysis","Presence or absence of local and distant relapse","from 3 to 5 years after surgery",null,{"allocation":41,"interventionModel":41,"interventionModelDescription":41,"primaryPurpose":41,"observationalModel":43,"timePerspective":44,"maskingInfo":41},"COHORT","RETROSPECTIVE","The use of neoadjuvant chemo-immunotherapy for the treatment of non-small cell lung cancer (NSCLC) is increasing. However, there is limited research comparing the feasibility and oncologic efficacy of robot-assisted thoracoscopic surgery (RATS), video-assisted thoracoscopic surgery (VATS), and open lung resection, in patients already treated with neoadjuvant chemo-immunotherapy. This study aims to evaluate the benefits of RATS compared to VATS and open surgery in terms of short-term outcomes for patients with NSCLC undergoing neoadjuvant chemo-immunotherapy.\n\nAll adult patients diagnosed with locally advanced and resectable NSCLC who underwent lung resection from 01-01-2016 to 31-03-2024 by robotic, VATS and open approach after receiving neoadjuvant chemo-immunotherapy will be included.\n\nPatients are divided into three groups: robotic lung resection; video-assisted thoracoscopic (VATS) lung resection; open lung resection.","Patients with diagnosed locally advanced and resectable non-small cell lung cancer (NSCLC) who underwent lung resection from 01-01-2016 to 31-03-2024 by robotic, video-assisted thoracoscopic (VATS), and open approaches after receiving neoadjuvant chemo-immunotherapy.",[48,51,54],{"label":49,"type":41,"description":50,"interventionNames":41},"Robotic Approach","Adult patients diagnosed with locally advanced and resectable non-small cell lung cancer (NSCLC) who underwent robotic lung resection",{"label":52,"type":41,"description":53,"interventionNames":41},"video-assisted thoracoscopic surgery (VATS) Approach","Adult patients diagnosed with locally advanced and resectable non-small cell lung cancer (NSCLC) who underwent video-assisted thoracoscopic surgery (VATS) lung resection",{"label":55,"type":41,"description":56,"interventionNames":41},"Open Approach","Adult patients diagnosed with locally advanced and resectable non-small cell lung cancer (NSCLC) who underwent open lung resection",[58],{"name":59,"role":60,"phone":61,"phoneExt":62,"email":63},"Pierluigi Novellis, Medical Doctor","CONTACT","0226437202","+39","novellis.pierluigi@hsr.it",[65,83,96,110,126,137],{"facility":66,"status":67,"city":68,"state":69,"zip":70,"country":71,"countryCode":72,"cosmosGeoPoint":73,"geoPoint":78,"contacts":79},"Baptist Health South Florida","RECRUITING","Miami","Florida","33176","United States","US",{"type":74,"coordinates":75},"Point",[76,77],-80.19366,25.77427,{"lat":77,"lon":76},[80],{"name":81,"role":60,"phone":41,"phoneExt":41,"email":82},"Mark R. Dylewski, MD","MarkD@baptisthealth.net",{"facility":84,"status":67,"city":85,"state":85,"zip":86,"country":71,"countryCode":72,"cosmosGeoPoint":87,"geoPoint":91,"contacts":92},"Memorial Sloan Kettering Cancer Center","New York","10065",{"type":74,"coordinates":88},[89,90],-74.00597,40.71427,{"lat":90,"lon":89},[93],{"name":94,"role":60,"phone":41,"phoneExt":41,"email":95},"Bernard J. Park, MD","parkb@mskcc.org",{"facility":97,"status":67,"city":98,"state":99,"zip":100,"country":71,"countryCode":72,"cosmosGeoPoint":101,"geoPoint":105,"contacts":106},"West Virginia University","Morgantown","West Virginia","26506",{"type":74,"coordinates":102},[103,104],-79.9559,39.62953,{"lat":104,"lon":103},[107],{"name":108,"role":60,"phone":41,"phoneExt":41,"email":109},"Alper Toker, MD","alper.toker@wvumedicine.org",{"facility":111,"status":67,"city":112,"state":113,"zip":114,"country":115,"countryCode":116,"cosmosGeoPoint":117,"geoPoint":121,"contacts":122},"Istituto Clinico Humanitas","Rozzano","Milan","20089","Italy","IT",{"type":74,"coordinates":118},[119,120],9.1559,45.38193,{"lat":120,"lon":119},[123],{"name":124,"role":60,"phone":41,"phoneExt":41,"email":125},"Giuseppe Marulli, MD","giuseppe.marulli@humanitas.it",{"facility":127,"status":67,"city":113,"state":41,"zip":128,"country":115,"countryCode":116,"cosmosGeoPoint":129,"geoPoint":133,"contacts":134},"Scientific Institute Ospedale San Raffaele","20132",{"type":74,"coordinates":130},[131,132],9.18951,45.46427,{"lat":132,"lon":131},[135],{"name":136,"role":60,"phone":61,"phoneExt":62,"email":63},"Pierluigi Novellis, MD",{"facility":138,"status":67,"city":139,"state":41,"zip":140,"country":115,"countryCode":116,"cosmosGeoPoint":141,"geoPoint":145,"contacts":146},"Regina Elena National Cancer Institute","Rome","00144",{"type":74,"coordinates":142},[143,144],12.51133,41.89193,{"lat":144,"lon":143},[147],{"name":148,"role":60,"phone":41,"phoneExt":41,"email":149},"Filippo Gallina, MD","filippo.gallina@ifo.it",{"type":151,"investigatorFullName":152,"investigatorTitle":153,"investigatorAffiliation":5,"oldNameTitle":41,"oldOrganization":41},"PRINCIPAL_INVESTIGATOR","Pierluigi Novellis","Principal Investigator",[155,156,157,159,160],{"name":84,"class":6},{"name":111,"class":6},{"name":158,"class":6},"Regina Elena Cancer Institute",{"name":66,"class":6},{"name":97,"class":6},"100564212",false,"NCT06626243","Analysis of RATS, VATS and Open Lung Resections After Neoadjuvant Chemo-immunotherapy in Patients Performed in Five Referred Centers","An International Multicenter Retrospective Analysis of RATS, VATS and Open Lung Resections After Neoadjuvant Chemo-immunotherapy","IMMUNORATS","Inclusion Criteria:\n\n* Diagnosis of clinical or pathological stage IIB (T1-2, hilar N1, M0) and III (any T, N1-2, M0) NSCLC surgically treated with robotic, VATS and open approach with radical intent from 1st of January 2016 to 31st of March 2024\n* Received neoadjuvant chemo-immunotherapy or immunotherapy alone\n* Age \\>= 18 years old at the moment of surgery\n\nExclusion Criteria:\n\n* Age \\\u003C18 years old at the moment of surgery","ALL","18 Years",{"count":171,"type":172},140,"ESTIMATED","OBSERVATIONAL","The study is a retrospective observational study. The study is designed to be multicentric and international and it will analyze medical records from selected patients diagnosed with locally advanced and resectable NSCLC who underwent lung resection by robotic, VATS and open approach after receiving neoadjuvant chemo-immunotherapy.\n\nThere are no risks for the patients, as this is a retrospective data collection.",[176],"Non-Small Cell Lung Cancer",[178,179,180],"Video-Assisted Thoracoscopic Surgery","Robot-Assisted Thoracoscopic Surgery","open approach","2024-11-26",{"date":183,"type":184},"2024-11-29","ACTUAL",{"date":186,"type":184},"2024-09-30",{"date":188,"type":172},"2025-10-15",{"name":5,"class":6},6]